



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10780,321		
		Filing Date	January 27, 2004		
		First Named Inventor	BUELOW, Roland		
		Group Art Unit	Not Yet Assigned 1644		
		Examiner Name	Not Yet Assigned M. S. Bruno		
Sheet	1	of	3	Attorney Docket Number	A-64360-2/TAL/NHT (465840-00087)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
MD	A1	5,385,888	01-31-1995	Goodenow et al.	
MD	A2	5,723,128	03-03-1998	Clayberger et al.	
MD	A3	5,753,625	05-19-1998	Buelow	
MD	A4	6,162,434	12-19-2000	Buelow et al.	
MD	A5	6,696,545 B1	02-24-2004	Buelow et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² Number ³ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
MD	B1	WO 88/05784	08-11-1988	Trustees of Stanford University		
MD	B2	WO 90/10016	09-07-1990	Regents of Univ. of California		
MD	B3	WO 93/08817	05-13-1993	Trustees of Stanford University		
MD	B4	WO 93/17699	09-16-1993	Trustees of Stanford University		
MD	B5	WO 94/02162	02-03-1994	Glycomed, Inc.		
MD	B6	WO 95/13288	05-18-1995	Trustees of Stanford University		
MD	B7	WO 96/22306	07-25-1996	No. Sydney Area Health SE		
MD	B8	WO 96/35443	11-14-1996	Sangstat Medical Corporation		
MD	B9	WO 97/24140 A1	07-10-1997	Trustees of Stanford University		
MD	B10	WO 97/44052 A1	11-27-1997	Trustees of Stanford University		
MD	B11	WO 97/44351 A1	11-27-1997	Trustees of Stanford University		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
MD	C1	ABRAHAM, R.J., et al., "Charge Calculations in Molecular Mechanics 7: Application to Polar Pi Systems Incorporating Nitro, Cyano, Amino, C=S and Thio Substituents," <i>J. Comput. Aided Molec. Des.</i> 3(2):175-187 (1989).			
MD	C2	ASHTON, M.J., et al., "New perspectives in lead generation II: Evaluating molecular diversity," <i>Disease Drug Ther.</i> 1(2):71-78 (Feb. 1996).			
MD	C3	BJORKMAN, P.J., et al., "Structure of the Human Class I Histocompatibility Antigen, HLA-A2," <i>Nature</i> 329(6139):506-512 (Oct. 1987).			
MD	C4	BLAESE, R.M., et al., "Gene therapy for primary immunodeficiency disease," <i>Immunodef. Rev.</i> 3(4):329-349 (Jan. 1992).			

Examiner Signature	<i>Marcus</i>	Date Considered	5/27/05
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 20313-1450. 1128597_1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/780,321		
		Filing Date	January 27, 2004		
		First Named Inventor	BUELOW, Roland		
		Group Art Unit	Not Yet Assigned 1644		
		Examiner Name	Not Yet Assigned M. DiBona		
Sheet	2	of	3	Attorney Docket Number	A-64360-2/TAL/NHT (465840-00087)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
MD	C5	BUELOW, R., et al., "Immunomodulation by soluble HLA class I," <i>Transplantation</i> 59:649-654 (Mar. 1995).	
MD	C6	BUELOW, R., et al., "Prolongation of Skin Allograft Survival in Mice Following Administration of ALLOTRAP," <i>Transplantation</i> 59(4):455-460 (Feb. 1995).	
MD	C7	CANTONI, L., et al., "Interleukin-1 and tumor necrosis factor induce hepatic haem oxygenase. Feedback regulation by glucocorticoids," <i>Biochem. J.</i> 279(3):891-894 (Nov. 1991).	
MD	C8	CUTURI, M.C., et al., "Prolongation of allogeneic heart graft survival in rats by administration of a peptide (a.a. 75-84) from the α 1 helix of the first domain of HLA-B7 01," <i>Transplantation</i> 59(5):661-669 (Mar. 1995).	
MD	C9	DAL PORTO, J., et al., "A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations," <i>Proc. Natl Acad. Sci. USA</i> 90(14):6671-6675 (Jul. 1993).	
MD	C10	FUKUDA, Y., et al., "Effect of interleukin-11 on the levels of MRNAs encoding heme oxygenase and haptoglobin in human HepG2 hepatoma cells," <i>Biochem. Biophys. Res. Commun.</i> 193(1):297-302 (1993).	
MD	C11	GAO, L., et al., "Both L- and D-isomers of allotrap 2702 prolong cardiac allograft survival in mice," <i>J. Heart Lung Transplant.</i> 15(1):78-87 (Jan. 1996).	
MD	C12	GRASSY, G., et al., "Computer-assisted rational design of immunosuppressive compounds," <i>Nat. Biotechnol.</i> 16(8):748-752 (Aug. 1998).	
MD	C13	GRASSY, G., et al., "Variable mapping of structure-activity relationships: application to 17-spirolactone derivatives with mineralocorticoid activity," <i>J. Mol. Graphics</i> 13(6):356-367 (Dec. 1995).	
MD	C14	HAIECH, J., et al., "Use of TSAR as a new tool to analyze the molecular dynamics trajectories of proteins," <i>J. Mol. Graphics</i> 13(1):46-48 (Feb. 1995).	
MD	C15	IYER, S., et al., "Characterization and biological significance of immunosuppressive peptide D2702.75-84(E->V) binding protein," <i>J. Biol. Chem.</i> 273(5):2692-2697 (Jan. 1998).	
MD	C16	KABAT, et al., "Sequences of Proteins of Immunological Interest," NIH publication no. 91-3242, 1:738-740, 770-771, 779-780, 788-789, and 802-804 (1991).	
MD	C17	MANOIOS, N., et al., "T-cell antigen receptor transmembrane peptides modulate T-cell function and T cell-mediated disease," <i>Nature Med.</i> 3(1):84-88 (Jan. 1997).	
MD	C18	NGO, et al., "The Protein Folding Problem and Tertiary Structure Prediction," K. Merz, Jr., and S. LeGrand (eds.), Birkhauser: Boston, MA, 491-495 (1994).	
MD	C19	NISCO, S., et al., "Induction of Allograft Tolerance in Rats by an HLA Class-I-derived Peptide and Cyclosporine A," <i>J. Immunol.</i> 152(8):3786-3792 (Apr. 1994).	
MD	C20	PRINGLE, J.H., (Direct Submission), NCBI Accession No. A38244 (GI2294842), 14 April 1994.	
MD	C21	STAGSTED, J., et al., "Regulation of insulin receptor functions by a peptide derived from a major histocompatibility complex class I antigen," <i>Cell</i> 62(2):297-307 (Jul. 1990).	
MD	C22	TUFVESON, G., et al., "New immunosuppressants: testing and development in animal models and the clinic: with special reference to DSG," <i>Immunol. Rev.</i> 136:99-109 (Dec. 1993).	
MD	C23	VISWANADHAN, V., et al., "Atomic Physicochemical Parameters for Three Dimensional Structure Directed Quantitative Structure - Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occurring Nucleoside Antibiotics," <i>J. Chem. Inf. Comput. Sci.</i> 29(3):163-171 (1989).	

Examiner Signature		Date Considered	5/27/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 20313-1450. 1128597_1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10780,321
				Filing Date	January 27, 2004
				First Named Inventor	BUELOW, Roland
				Group Art Unit	Not Yet Assigned 1644
				Examiner Name	Not Yet Assigned M. DiBrito
Sheet	3	of	3	Attorney Docket Number	A-64360-2/TAL/NHT (465840-00087)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MD	C24	WILLIS, D., et al., "Heme oxygenase: a novel target for the modulation of the inflammatory response," <i>Nat. Med.</i> 2(1):87-90 (Jan. 1996).	
MD	C25	YASRI, A., et al., "Rational choice of molecular dynamics simulation parameters through the use of the three-dimensional autocorrelation method: application to calmodulin flexibility study," <i>Protein Eng.</i> 9(11):959-976 (Nov. 1996).	

Examiner Signature		Date Considered	5/27/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English Language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Alexandria, VA 20313-1450. 1128597_1